Publications by authors named "J Auge"
Article Synopsis
- Neuroimaging and fluid biomarkers, like MRI and cerebrospinal fluid (CSF) analysis, help distinguish frontotemporal dementia (FTD) from Alzheimer's disease (AD).
- A machine learning algorithm was developed to calculate individual probabilistic scores, yielding an 82% accuracy rate for differentiating between AD and FTD using MRI alone.
- Combining MRI data with CSF biomarkers improved diagnostic accuracy and confidence, making the algorithm a promising tool for clinical use, especially in scenarios with limited access to expert diagnoses.
Article Synopsis
- Early-onset Alzheimer's disease (EOAD) has more severe neuropsychiatric symptoms and lower integrity of the locus coeruleus (LC) compared to late-onset Alzheimer's disease (LOAD).
- A study involving 104 subjects with AD and 32 healthy controls used MRI and other measurements to analyze the differences in LC integrity and symptoms between EOAD and LOAD.
- Results showed that EOAD's lower LC integrity correlates with increased neuropsychiatric symptoms, and its greater degeneration may explain these severe symptoms compared to LOAD.
Article Synopsis
- Tumor markers (TMs) are special molecules that help doctors find out if someone has cancer and how they're doing treatment.
- Sometimes these markers can show up even when a person is healthy, which can lead to doctors thinking there's a problem when there's not.
- The review looks at many studies from 1970 to 2023 to understand why false results happen and how knowing more about these markers can help doctors make better decisions.
Introduction: This study assesses the accuracy of neutrophil activation markers, including neutrophil extracellular traps (NETs) and calprotectin, as biomarkers of disease activity in patients with established rheumatoid arthritis (RA). We also analyse the relationship between NETs and various types of therapies as well as their association with autoimmunity.
Methods: Observational cross-sectional study of patients with RA receiving treatment with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (JAK-inhibitors) for at least 3 months.
Article Synopsis
- Plasma biomarkers, particularly p-tau181, GFAP, and NfL, show promise in identifying amyloid beta (Aβ) pathology, but other factors affecting their levels need to be understood before clinical use.
- In a study of 360 patients, eGFR was the only significant factor affecting p-tau181 levels, while age, BMI, and comorbidities influenced GFAP and NfL concentrations.
- Despite these relationships, the diagnostic accuracy of p-tau181 for determining Aβ status remained high at 87%, indicating minimal impact from confounding factors, suggesting its strong potential for clinical application.